Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO7806767 alone and with pembrolizumab in advanced solid tumors
NL-OMON61591Phase 1Not yet recruiting
- Sponsor
- Roche
- Start
- Sep 2026
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1 trial of YL211 and pembrolizumab in Nonhematologic neoplasms (2 arms), sponsored by Roche. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
YL211pembrolizumab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON61591.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61591.